By Anna Everette The title of this article is partially borrowed from a fascinating Lightning Presentation delivered by John Doench of Broad Institute at CRISPRcon this year. In his talk, Mr. Doench pointed out how we’ve been looking up to this promising technology for a while now, hoping it will deliver the anticipated results (see […]
The Hope of CRISPRcon: Year 2, Guest Post by Anna Everette Read More »
The last few years for the publicly-traded stem cell clinic biz, US Stem Cell, Inc., which goes by the ticker $USRM, have seemed like a rollercoaster to me as an observer. I can see four main areas of news that to me make the future seem uncertain for this firm. First, the US Stem was linked to the
Clinic biz US Stem Cell reports SEC subpoena, adding to uncertainty on its future Read More »
Early in 2016, we started hearing about patient allegations of having been blinded in Florida by at least one stem cell business and several allegations seemed linked to a publicly-traded company called U.S. Stem Cell, Inc. (USRM). In turn, there have been a number of lawsuits involving USRM, including one filed just a few months
Sen. Grassley asks tough questions for FDA on U.S. Stem Cell, blinded women Read More »
What is stem cell media? When us scientists hear the phrase “stem cell media” we usually think about the liquid food that we feed our stem cells in the lab, which resembles a kind of nutrient-rich Kool-aid, but another kind of stem cell media consists of the news coverage of stem cells. This other kind
Grading 3 stem cell media reports on clinical science: vision, MS, & paralysis Read More »
When I read about a stem cell penis growth injection, what comes to mind first when you read that is “Ow!” The goal of today’s post is to fact-check this whole area. What’s in this article Stem cell penis growth | Risks |US Stem Cell Clinic claims |Does it work? | Does size matter? | Data check
Stem cell penile growth fact check Read More »
The recent news that Texas A&M University has inked a full-blown deal with the direct-to-consumer stem cell clinic firm Celltex struck me as an unusual development. Recently we’ve seen more universities exploring the use of stem cells outside of the traditional FDA clinical trial process that is fundamentally based on an investigational new drug application (IND). Some
Why did Texas A&M ink big deal with stem cell clinic firm Celltex on exosomes? Read More »
Today’s post includes a list of firms/products that have self-reported that they have received FDA regenerative medicine advanced therapy designation or RMAT. Sometimes people call these “r mat” with a space. As of December 12, 2023 there are 85 RMATs in the public domain. I also include FDA data on RMAT submissions via an FDA RMAT resource
Updated FDA granted RMAT List (85) Read More »
The FDA started off 2018 with a bang on the direct-to-consumer stem cell clinic front with a warning letter on January 3rd to American CryoStem, a firm involved in processing and distributing adipose stem cells. The company’s ATCELL™ adipose stem cell product was the focus of much of letter. The FDA indicated in the warning
FDA Issues 1st Stem Cell Warning Letter of 2018 to American CryoStem Read More »
The idea of using stem cells for scleroderma seems a bit more promising today. A new NIH-funded study reported in the New England Journal of Medicine (NEJM) gives some hope for the use of a combination of a specific type of myeloablation and a transplant of hematopoietic stem cells (HSC). This approach yields improved long-term
Stem cells for scleroderma, new NEJM article reports promise Read More »
Some conditions like Huntington’s Disease are so bad and there are no treatments such that any bit of encouraging news can be cause for legitimate excitement, but at the same time things can go too far potentially, especially if there is news coverage not backed up by a published paper or some other definitive source
Hope & hype on unpublished Huntington’s Disease trial splashy news Read More »